Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 19/20 | 1.00 |
| ▸ | KCNK9 | Q9NPC2 | 19/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18963276 | 1.00 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL18963203 | 0.89 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL22260962 | 0.89 | KCNK3 (0.85) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL18963278 | 0.88 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29432725 | 0.88 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL22260967 | 0.87 | KCNK3 (0.85) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL29458044 | 0.86 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963200 | 0.86 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL20531046 | 0.85 | KCNK3 (0.91) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL29432726 | 0.85 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| EP-4452246-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118102-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| US-20220218700-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-14 | — | — | US | disclosed |
| EP-3965762-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3965766-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218700-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, ADRA1D | KCNK3 178/4885KCNK9 702/4885SLC2A1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.